Research trends and hotspots in clinical trials of migraine in the past 20 years: bibliometric analysis.

Migraines are more than just bad headaches. They're a recurring neurological condition that can cause severe throbbing pain, nausea, vomiting, and extreme sensitivity to light and sound. For millions of people, migraines can disrupt daily life, work, and relationships — and when not managed well, they can become chronic.

A new study published in Frontiers in Neurology took a broad look at 20 years of migraine research. Scientists analyzed 1,129 clinical studies published between 2004 and 2023 to identify what researchers have been focusing on and where the field is heading. Using special visualization tools, they mapped out the most important themes, authors, and discoveries in migraine science.

What did they find? Migraine research has been growing steadily, with increasing attention on topics like how well treatments work, what makes migraines worse, and how migraines connect to other conditions like depression and disability. One of the biggest areas of excitement is a protein called CGRP (calcitonin gene-related peptide), which plays a key role in migraine attacks. New medications targeting CGRP have changed how doctors treat and prevent migraines. Researchers are also looking at real-world effectiveness — meaning how treatments perform outside of clinical trials in everyday patients.

For people living with migraines, this research signals good news: the medical community is investing heavily in better, more personalized treatments. But many patients are also turning to acupuncture as a drug-free option to reduce the frequency and severity of their migraines. Acupuncture has been studied as both a preventive and acute migraine treatment, with growing evidence supporting its use alongside or instead of medication.

If you're considering acupuncture for migraine relief, seek out a licensed, board-certified acupuncturist with experience treating neurological and pain conditions.

This bibliometric analysis in Frontiers in Neurology examined 1,129 migraine clinical trial publications across 389 journals from 61 countries, spanning 2004–2023, using CiteSpace and VOSviewer for knowledge graph mapping. The United States and Albert Einstein College of Medicine led in output, with Richard B. Lipton identified as the most prolific contributor. The journal Headache recorded the highest publication and citation volume. Dominant research keywords included 'CGRP,' 'RCT,' 'prophylaxis,' 'disability,' 'depression,' 'questionnaire,' and 'real-world effectiveness,' reflecting a field increasingly focused on mechanistic precision and patient-reported outcomes. No individual effect sizes are reported, as this is a bibliometric rather than interventional study. Clinically, the analysis signals that CGRP-targeted therapies and epigenetic research are shaping the next wave of migraine management. For acupuncture practitioners, the emphasis on non-pharmacological options, comorbidity management (especially depression), and real-world effectiveness aligns well with positioning acupuncture as an evidence-informed, integrative component of comprehensive migraine care.